

PANDEMIC INFLUENZA RESPONSE PLAN

SECTION NINE - VACCINES TABLE OF CONTENTS

	Page #
1) Target Audience / Introduction / Assumptions.....	9-1
2) Mass Immunization	9-3
3) Vaccine Update, Vaccine Management, Vaccine Distribution and Vaccine Security Plan.....	9-4
4) Inventory & Tracking	9-5
5) Vaccine Storage, Handling and Monitoring “Cold Chain” Procedure (Draft) Summary.....	9-5
6) Informed Consent for Immunization Procedure Summary	9-5
7) Immunization Administration Procedure Summary	9-6
8) Adverse Event Following Immunization Reporting Procedure Summary	9-6
9) Documentation Tools	9-6
10) Resources	9-6
11) Tools	
i. Tool 9.1 Inventory Supply Log for Influenza Vaccine	9-7
ii. Tool 9.2 Influenza Vaccine/Anaphylaxis Medications Pharmacy Order/ Return Form.....	9-9
iii. Tool 9.3 Pandemic Client Surveillance Form	9-10
12) Appendix A: Mass Prophylaxis/Immunization Clinic (Restricted).....	9-11

VACCINES

Target Audience

Immunization providers such as public health nurses, immunization nurses, registered nurses, physicians and other staff in facilities may be responsible for storage, handling and transportation (i.e. pharmacist, pharmacy technician, EMS, maintenance, administrative support).

Introduction

Influenza immunization has been considered the cornerstone of influenza prevention and control and will also serve as the central preventive strategy during the next pandemic.

The objectives of the pandemic vaccine program (as stated in the Canadian Pandemic Influenza Plan) are to:

- Provide a safe and effective vaccine program to all Canadians as quickly as possible
- Allocate, distribute and administer vaccine as rapidly as possible to the appropriate groups of people
- Monitor the safety and effectiveness of vaccination programs

Pandemic vaccine programs should be flexible and continue to evolve based on the best information available at any given time.

Assumptions:

In order to plan for an event that in many ways is unpredictable the Canadian Pandemic Plan provides a set of assumptions that have specific implications for pandemic vaccine programs.

- The next pandemic will first emerge outside of Canada
 - *The virus to be used for the pandemic vaccine will be isolated outside of Canada and sent to the manufacturer as a “primary seed lot.” The government does not have control over when this will occur.*
- The next pandemic virus will be present in Canada within three months after it emerges in another part of the world, but it could be much sooner because of the volume and speed of global air travel.
 - *There will likely be cases of pandemic influenza in Canada prior to the availability of vaccine.*
- The first peak of illness in Canada could occur within two to four months after the virus arrives. The first peak in mortality is expected to be approximately one month after the peak in illness.
 - *There will likely be deaths due to pandemic influenza in Canada before the availability of vaccine.*

- The impact of the pandemic in terms of severity, age distribution and extent of spread may be different from annual influenza; however, this will not be known until the novel virus starts spreading efficiently in the human population.
 - *It will not be possible to identify in advance of the pandemic the individual risk factors for poor outcome of infection with the specific pandemic influenza virus.*
- Individuals who recover from illness caused by the pandemic strain will be immune to further infection by that strain.
 - *Those with a history of illness attributed to the pandemic virus may be considered at lower priority for immunization if prioritization is necessary.*
- A pandemic vaccine will become available in time to have an effect on the impact of the pandemic in Canada. The extent of the effect will largely depend on the timing of vaccine availability in comparison to the pandemic activity in Canada.
- Two doses of vaccine will be needed in order to optimize protection. The two doses would be given approximately one month apart.
- Because of cross-protection, a vaccine developed from a strain isolated early in the pandemic will still be beneficial should the pandemic virus “drift” over the course of the pandemic.
- The new pandemic vaccine is not likely to be 100% effective, but even a vaccine with relatively low efficacy (e.g. 30%) will help curb the effect of the pandemic.
- There will be limited information regarding vaccine safety before the rollout of the immunization campaign.
- Concern regarding vaccine safety and reactogenicity will likely be inversely proportional to the severity of the pandemic in Canada.
- Depending on the timing of the pandemic and availability of the pandemic vaccine, seasonal influenza immunization programs may not be initiated or completed, as the pandemic vaccine program is the priority.

Prioritization

It is expected to take several months to develop and produce a pandemic vaccine and it is anticipated that the vaccine will become available in lots. This requires that decisions will need to be made regarding how these doses will be distributed across Canada and whether to prioritize certain subgroups of the population ahead of others.

At this time, according to the Canadian Pandemic Plan there is no policy decision regarding distribution of the first doses of vaccine across Canada. The Canadian Pandemic Plan identifies population subgroups, with definitions of each and examples of who might be included in each group. Determining the order in which these subgroups would receive vaccine must take into consideration several factors, many of which will not be known until the pandemic occurs. Some of these factors may be:

- Impact on pandemic goals (i.e. minimizing serious illness, overall deaths and societal disruption)
- Operational considerations (i.e. size of group, ease of identification and accessibility)
- Severity/epidemiology of the pandemic
- Difference in vaccine effectiveness between groups
- Timing of vaccine availability
- Public opinion and risk perception as a consideration (e.g. perceived severity of the pandemic and risks of the vaccine)

When available it is important that the vaccine be distributed in an equitable, efficient, consistent, secure and timely manner across the region.

Mass Immunization

Mass immunization clinics are the most cost effective method for providing immunization to a large number of people over a short time period. It is expected that planning for mass clinics will be based on:

- Directives from Public Health Agency of Canada or Manitoba Health for priority group immunization.
- The annual ARHA influenza program.
- The availability of vaccine distribution and storage.
- The ARHA Quality Framework.

Planning should consider whether (and how) one dose of vaccine could be administered to the entire population within one month. If this is not feasible, determine what the fastest achievable and sustainable administration rate is for the region when human and other resources may be limited. Planners should develop methods of identifying the numbers for each population subgroup, as well as how to identify and target these individuals. They must also be prepared to implement both a non-prioritized and prioritized pandemic immunization program.

This plan will also work for mass prophylaxis clinics, where antivirals may be distributed to target populations. An overview of the guidelines for setting up and managing a mass clinic is given in Appendix A, Section 9 ARHA Pandemic Influenza Response Plan. (Secure access, password required).

Communication:

A communication plans need to be developed to ensure communication channels are in place to:

- Update key players at local levels
- Provide the public with information
- Facilitate implementation of the program
- Mobilize resources required to rapidly implement mass immunization clinics

Please refer to Section 7 – Communications for more detail.

Vaccine Uptake:

It is important to be prepared to immunize 100% of the population; however, the actual proportion of the population that will voluntarily seek vaccination will depend on public perception of the risk and the severity of the disease. Therefore, it would be prudent to prepare for an initial demand of 75% of the target population.

Vaccine Management:

The objectives of vaccine management are:

- To track, store, distribute, allocate and administer vaccine/prophylaxis and supplies safely, securely, efficiently and appropriately.
- To monitor vaccination rates by population subgroups.
- To monitor unusual/adverse events following immunization.

Vaccine Distribution

Manitoba has a vaccine distribution system in place to support all existing immunization programs in the province. When a pandemic vaccine becomes available the federal government will secure supplies of the vaccine and distribute it to provinces and territories on an equitable basis. Manitoba Health will maintain the provincial vaccine depot and distribute the vaccine to regional health authorities. *(In the ARHA the regional receiving depot/s may distribute vaccine within the region as needed. Refer to Appendix A).* Please refer to Section 11 - Safety & Security / Materials Management (Secure access, password required) for Vaccine transportation.

Vaccine Security Plan

Safety and security are vital considerations in a pandemic situation where supplies may be limited and fear and anxiety may be widespread. All mass vaccination campaigns require security measures to address the safety of staff, clients and supplies. Vaccine security is also needed during transport and storage. See Safety and Security / Materials Management Section 11 (Secure access, password required).

Inventory and Tracking

Once pandemic vaccine arrives in the region, each dose must be accounted for from its arrival at the regional depot until administration to the client.

Inventory Supply Log for Influenza Vaccine **Tool 9.1**

Once received the regional depot pharmacist will enter the name of the vaccine, the lot numbers and the quantity of vaccine received on this form. When vaccine is distributed to sites across the region, pharmacy will record the location sent, number of doses shipped and lot numbers.

Influenza Vaccine/Anaphylaxis Medications Pharmacy Order/Return Form **Tool 9.2**

The PHN will fill out and fax this form to order from/return vaccine to the regional pharmacy depot. This form will accompany all shipments. Upon receipt of vaccine signature is required to verify inventory received and temperature monitoring.

Tracking/Recall for two-dose system:

It is assumed that for a two-dose program, completion of the second dose (approximately one month after the first) should be carried out as soon as possible to effect immunity. Administration of the second dose should not wait until after every priority group has received a first dose. This strategy will require extensive planning that involves record-keeping, tracking and recall mechanisms. These strategies should be developed with input from IT and MIMS clerks.

Vaccine Storage, Handling and Monitoring “Cold Chain” Procedure (Draft) Summary

Safe and immunogenic vaccine products will be provided to clients by all vaccine providers in the region. Quality control measures will be implemented in accordance with the National Guidelines for Vaccine Storage and Transportation and the ARHA Vaccine Storage, Handling and Monitoring “Cold Chain” Procedure.

Informed Consent for Immunization Procedure Summary

Refer to Informed Consent for Immunization Policy (RCPM 10-C-010)

All immunizations are voluntary in Manitoba. The process of obtaining informed consent is a requirement supported by the Canadian National Advisory Committee on Immunization (NACI), the College of Physicians and Surgeons of Manitoba, College of Registered Nurses of Manitoba, College of Registered Psychiatric Nurses and the College of Licensed Practical Nurses and in accordance with the Assiniboine Regional Health Authority, Informed Consent for Health Care Intervention (ADM-XII-310).

Pandemic Client Surveillance Form **Tool 9.3**

Immunization Administration Procedure Summary

Refer to Procedure for Immunization Administration (RCPM 10-C-011)

The Registered Nurse/Immunization Provider will, when giving any vaccine, ensure safe and accurate administration. All clients will be assessed prior to vaccine administration. Vaccines will be administered using the recommended injection technique and appropriate supplies and equipment.

Adverse Event Following Immunization Reporting (AEFI) Procedure Summary

Refer to Adverse Event Following Immunization Reporting (AEFI) Procedure (RCPM 10-C-013)

All adverse events following immunization occurring in the Assiniboine Regional Health Authority will be appropriately recorded by health care providers and submitted to the Division of Immunization of the Bureau of Infectious Diseases of Health Canada via Manitoba Health.

An enhanced plan may need to be developed and in place to monitor vaccine safety and to ensure the timely communication of any potential adverse event following immunization during the pandemic.

Documentation Tools

Tool 9.1 Inventory Supply Log for Influenza Vaccine

Tool 9.2 Influenza Vaccine/Anaphylaxis Medications Pharmacy Order/Return Form

Tool 9.3 Pandemic Client Surveillance Form

Resources:

- BC Pandemic Influenza Preparedness Plan
- Canadian Pandemic Influenza Plan
- Vancouver Coastal Health Pandemic Influenza Plan
- Ontario Health Plan for an Influenza Pandemic
- Toronto Pandemic Influenza Plan 2005
- Manitoba Health

Tool 9.1 Inventory Supply Log for Vaccine

Date: _____ **Clinic:** _____ **Nurse Signature:** _____

Lot #	Doses Administered	Doses Wasted	Doses Remaining	Nurses Initials

Hand in Inventory Supply Log for Vaccine to Immunization Team Leader at end of shift.

Tool 9.1 Inventory Supply Log for Vaccine

To be completed by Immunization Team Leader or Clinic Manager at the beginning and end of each clinic shift (i.e. 9:00am to 3:00pm; 3:00pm to 9:00pm)

Date: _____ **Time:** _____

Community Clinic: _____ **Location:** _____

Immunization Team Leader / PHN: _____

Vaccine Inventory:

Time	Lot #	# of Vials brought to clinic	# of Vials Added during clinic	# of Vials returned at end of clinic	Nurses Signature

Tool 9.2 Influenza Vaccine / Anaphylaxis Medications Pharmacy Order/Return Form

To be used when ordering or returning Influenza Vaccine and Anaphylaxis Medications from/to the Regional Pharmacy Depot FAX 476-2901; Phone 476-7824. Please include in shipping box.

Facility: _____

Date: _____

Address: _____

Contact Person: _____

Order No. (completed by Pharmacy): _____

Telephone: _____

Product Requested from Depot

Fax: _____

Product Returned to Depot

Product	# Vials Ordered	# Vials Sent	Lot Number		# Vials Returned	Lot Number	Comments
Vaccine: Vaxigrip (10 doses per vial)							
Vaccine:Fluviral (10 doses per vial)							
Epinephrine 1:1000							
Diphenhydramine 50 mg/mL							

SENDING	TRANSPORT	FINAL DESTINATION
Name: _____ Date: ___/___/___ Time:__:__ hrs Current Fridge Temp. when Vaccine Packed: _____ Packed with Thermometer _____ OR Cold/Warm Marker Indicator: _____ Signature: _____	Name: _____ Date: ___/___/___ Time:__:__ hrs Temp: Min _____ Max _____ Cold/Warm Marker Indicator: _____ Signature: _____	Name: _____ Date: ___/___/___ Time:__:__ hrs Temp: Min _____ Max _____ Cold/Warm Marker Indicator: _____ Signature: _____

Signature demonstrates accurate receipt /acceptance of product.

Tool 9.3

Pandemic Client Surveillance Form

Receptionist

Community Clinic

Date

Client Information:

Surname _____ Legal First Name _____ Initial _____ Date of Birth _____ PHIN _____
 yyyy / mm / dd

Client Phone Number: _____ Receptionist Initials _____

Identification Document(s)

Drivers License _____ Student Card _____
 Manitoba Health Card _____ Passport _____
 Birth Certificate _____ Other _____

Nursing Assessment

Reason for Immunization: Priority Group
 1 2 3 4 5 6

Health History Review:
 Have you had a flu shot before? Yes No
 Are you well today? Yes No, If NO explain _____
 Do you have any allergies? No Yes, If YES _____
 Are you currently on antibiotics for an infection? No Yes, If YES _____
 Have you had a reaction to a vaccine in the past? No Yes, If YES, _____

Reviewed contraindications and side effects; explained how to manage side effects.

Refer to Medical: Reason _____

Informed Consent Obtained
 Yes, I do consent to the person named above receiving the vaccine.
 No, I do not consent to the person named above receiving the vaccine.
 Alternate Decision Maker: Signature _____ Relationship _____

RN Signature: _____ **Refer to Immunization Nurse:**

Immunization Nurse

Dose 1 <input type="checkbox"/> Date _____ Vaccine: _____ Lot # _____ Dose: <u>Circle:</u> 0.5 mL IM (for 3 yrs & older) <u>or</u> 0.25 mL IM (for children 6-35 mths) Site: <u>R or L</u> <input type="checkbox"/> Deltoid <input type="checkbox"/> Vastus Lateralis RN Signature: _____	Dose 2 <input type="checkbox"/> Date _____ Vaccine: _____ Lot #: _____ Dose: <u>Circle:</u> 0.5 mL IM (for 3 yrs & older) <u>or</u> 0.25 mL IM (for children 6-35 mths) Site: <u>R or L</u> <input type="checkbox"/> Deltoid <input type="checkbox"/> Vastus Lateralis RN Signature: _____
--	---

MIMS Data Entry

Immunization(s) entered into MIMS Dose #1 _____ Dose #2 _____
 Date/Initial Date/Initial

Medical Assessment: _____

Physician Signature _____ **Date:** _____